RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
Clinical trials for RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New cell therapy takes aim at Hard-to-Treat blood cancers
Disease control Not yet recruitingThis early-stage study tests a new treatment called LVIVO-TaVec122 in 48 adults with B-cell blood cancers that have come back or not responded to standard therapy. The main goals are to check safety, find the right dose, and measure how long the treatment lasts in the body. It is…
Matched conditions: RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New shot for tough blood cancers enters first human tests
Disease control Not yet recruitingThis early-stage study tests a new drug called QLS2313 in 124 adults with blood cancers (like lymphoma or leukemia) that returned or didn't respond to standard treatments. The main goal is to check safety and find the right dose, not to cure the disease. Participants receive the …
Matched conditions: RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC